| Medivir Group |
2012 |
2011 |
2010 |
2009 |
2008 |
2007 |
|
| EBITDA (sek 000) |
-150,975 |
135,348 |
-128,851 |
-129,425 |
-103,410 |
-13,644 |
|
| EBIT (sek 000) |
-185,792 |
111,914 |
-136,726 |
-139,815 |
-113,733 |
-37,320 |
|
| Operating margin, % |
-33.5 |
16.0 |
-222.2 |
-544.4 |
-117.0 |
-15.0 |
|
| Profit margin, % |
-34.8 |
15.9 |
-218.1 |
-527.1 |
-102.9 |
-11.6 |
|
| Debt gearing, multiple |
0.1 |
0.2 |
0.0 |
0.1 |
0.0 |
0.0 |
|
| Return on: |
|
|
|
|
|
|
|
| equity, % |
-22.2 |
13.4 |
-35.3 |
-61.3 |
-29.5 |
-10.3 |
|
| capital employed, % |
-14.8 |
14.2 |
-35.2 |
-61.2 |
-29.6 |
-9.9 |
|
| total capital, % |
-14.0 |
12.7 |
-28.8 |
-46.8 |
-23.9 |
-7.6 |
|
| Equity ratio, % |
81.3 |
80.7 |
83.7 |
75.0 |
77.4 |
83.7 |
|
| Average number of shares, 000 |
31,257 |
29,924 |
24,718 |
20,844 |
20,844 |
16,873 |
|
| Number of shares at year-end, 000 |
31,260 |
31,254 |
28,593 |
20,844 |
20,844 |
20,844 |
|
| Basic and diluted earnings per share, sek |
-7.01 |
3.80 |
-5.43 |
-6.49 |
-4.76 |
-1.74 |
|
| Equity per share before and after dilution, sek |
27.99 |
35.05 |
21.24 |
7.38 |
13.80 |
18.42 |
|
| net worth per share before and after dilution, sek |
27.99 |
35.05 |
21.24 |
7.38 |
13.80 |
18.42 |
|
| Cash flow per share after investments, sek |
-4.69 |
-4.26 |
-3.34 |
-6.76 |
-2.14 |
-4.91 |
|
| Cash flow per share after financing activities, sek |
-7.66 |
-3.71 |
20.39 |
-6.76 |
-2.14 |
7.95 |
|
| Dividend per share, sek |
0 |
0 |
0 |
0 |
0 |
0 |
|
| Number of outstanding share warrants |
394,400 |
712,507 |
803,647 |
760,000 |
970,000 |
970,000 |
|
